

# Fernanda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10065134/publications.pdf>

Version: 2024-02-01

36  
papers

825  
citations

516710

16  
h-index

526287

27  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins. <i>Microbial Pathogenesis</i> , 2022, 162, 105341.	2.9	3
2	Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion. <i>Science Advances</i> , 2022, 8, eabn7424.	10.3	14
3	Digitoxigenin presents an effective and selective antileishmanial action against <i>Leishmania infantum</i> and is a potential therapeutic agent for visceral leishmaniasis. <i>Parasitology Research</i> , 2021, 120, 321-335.	1.6	11
4	Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against <i>Leishmania infantum</i> and is therapeutic against visceral leishmaniasis. <i>Experimental Parasitology</i> , 2021, 221, 108059.	1.2	11
5	<i>Leishmania</i> eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against <i>Leishmania infantum</i> infection. <i>Microbial Pathogenesis</i> , 2021, 151, 104745.	2.9	3
6	Acarbose presents in vitro and in vivo antileishmanial activity against <i>Leishmania infantum</i> and is a promising therapeutic candidate against visceral leishmaniasis. <i>Medical Microbiology and Immunology</i> , 2021, 210, 133-147.	4.8	9
7	<i>In vitro</i> and <i>in vivo</i> antileishmanial activity of $\hat{2}$ -acetyl-digitoxin, a cardenolide of <i>Digitalis lanata</i> potentially useful to treat visceral leishmaniasis. <i>Parasite</i> , 2021, 28, 38.	2.0	6
8	A <i>Leishmania infantum</i> hypothetical protein evaluated as a recombinant protein and specific B-cell epitope for the serodiagnosis and prognosis of visceral leishmaniasis. <i>Acta Tropica</i> , 2020, 203, 105318.	2.0	9
9	A <i>Leishmania</i> amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. <i>Cellular Immunology</i> , 2020, 356, 104194.	3.0	5
10	Biotechnological applications from a <i>Leishmania</i> amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis. <i>Microbial Pathogenesis</i> , 2020, 147, 104283.	2.9	6
11	<i>Leishmania infantum</i> pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis. <i>Molecular Immunology</i> , 2020, 124, 161-171.	2.2	7
12	A new <i>Leishmania</i> hypothetical protein can be used for accurate serodiagnosis of canine and human visceral leishmaniasis and as a potential prognostic marker for human disease. <i>Experimental Parasitology</i> , 2020, 216, 107941.	1.2	5
13	Evaluation of <i>Leishmania infantum</i> pyridoxal kinase protein for the diagnosis of human and canine visceral leishmaniasis. <i>Immunology Letters</i> , 2020, 220, 11-20.	2.5	8
14	A clioquinol-containing Pluronic <sup>®</sup> F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model. <i>Parasite</i> , 2020, 27, 29.	2.0	22
15	An immunoproteomics approach to identify <i>Leishmania infantum</i> proteins to be applied for the diagnosis of visceral leishmaniasis and human immunodeficiency virus co-infection. <i>Parasitology</i> , 2020, 147, 932-939.	1.5	7
16	A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against <i>Leishmania</i> species that cause tegumentary and visceral leishmaniasis. <i>Parasitology International</i> , 2019, 73, 101966.	1.3	15
17	Immunodiagnosis of human and canine visceral leishmaniasis using recombinant <i>Leishmania infantum</i> Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope. <i>Journal of Immunological Methods</i> , 2019, 474, 112641.	1.4	11
18	Screening diagnostic candidates from <i>Leishmania infantum</i> proteins for human visceral leishmaniasis using an immunoproteomics approach. <i>Parasitology</i> , 2019, 146, 1467-1476.	1.5	17

#	ARTICLE	IF	CITATIONS
19	Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis. <i>Experimental Parasitology</i> , 2019, 199, 30-37.	1.2	13
20	Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection. <i>Molecular Immunology</i> , 2019, 106, 108-118.	2.2	20
21	In silico Leishmania proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 87, 89-97.	2.4	16
22	A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. <i>Parasitology International</i> , 2019, 68, 63-72.	1.3	26
23	In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic® F127-based polymeric micelle system against Leishmania amazonensis infection. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 779-787.	5.6	27
24	Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against <i>Leishmania infantum</i> and <i>Leishmania amazonensis</i> Species. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 236-246.	2.5	35
25	Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species. <i>Parasitology Research</i> , 2018, 117, 391-403.	1.6	26
26	Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. <i>Translational Research</i> , 2018, 200, 18-34.	5.0	29
27	A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis. <i>Cytokine</i> , 2018, 111, 131-139.	3.2	18
28	Whole genome analysis of a schistosomiasis-transmitting freshwater snail. <i>Nature Communications</i> , 2017, 8, 15451.	12.8	216
29	A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection. <i>Immunobiology</i> , 2017, 222, 251-260.	1.9	18
30	A vaccine combining two Leishmania braziliensis proteins offers heterologous protection against Leishmania infantum infection. <i>Molecular Immunology</i> , 2016, 76, 70-79.	2.2	29
31	A next-generation proteome array for Schistosoma mansoni. <i>International Journal for Parasitology</i> , 2016, 46, 411-415.	3.1	22
32	Poloxamer 407 (Pluronic® F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. <i>Experimental Parasitology</i> , 2016, 169, 34-42.	1.2	41
33	Use of Humanised Rat Basophilic Leukaemia Cell Line RS-ATL8 for the Assessment of Allergenicity of Schistosoma mansoni Proteins. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3124.	3.0	21
34	Serological Screening of the Schistosoma mansoni Adult Worm Proteome. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2745.	3.0	48
35	Molecular analysis of SmFes, a tyrosine kinase of Schistosoma mansoni orthologous to the members of the Fes/Fps/Fer family. <i>Biochemical and Biophysical Research Communications</i> , 2007, 360, 163-172.	2.1	11
36	Schistosoma mansoni: Expression of Fes-like tyrosine kinase SmFes in the tegument and terebratorium suggests its involvement in host penetration. <i>Experimental Parasitology</i> , 2007, 116, 225-232.	1.2	28